Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | VCAM1 | P19320 | 4/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3537007 | 0.94 | KMT2A (0.40) | KMT2AMEN1TSHRALDH1A1LMNA | |
| SCHEMBL8996129 | 0.92 | KMT2A (0.39) | KMT2AMEN1TSHRALDH1A1LMNA | |
| SCHEMBL8996230 | 0.92 | KMT2A (0.39) | KMT2AMEN1TSHRALDH1A1LMNA | |
| SCHEMBL3940182 | 0.92 | KMT2A (0.39) | KMT2AMEN1TSHRALDH1A1LMNA | |
| SCHEMBL17337909 | 0.89 | KMT2A (0.48) | KMT2AMEN1TSHRALDH1A1LMNA | |
| SCHEMBL4953772 | 0.89 | KMT2A (0.44) | KMT2AMEN1TSHRALDH1A1LMNA | |
| SCHEMBL25495837 | 0.87 | KMT2A (0.43) | KMT2AMEN1TSHRALDH1A1LMNA | |
| SCHEMBL21049231 | 0.87 | KMT2A (0.43) | KMT2AMEN1TSHRALDH1A1LMNA | |
| SCHEMBL522462 | 0.87 | KMT2A (0.43) | KMT2AMEN1TSHRALDH1A1LMNA | |
| SCHEMBL8003191 | 0.84 | KMT2A (0.41) | KMT2AMEN1TSHRALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723529-B2 | Process for preparing nitrooxy esters, nitrooxy thioesters nitrooxy carbonates and nitrooxy thiocarbinates, intermediates useful in said process and preparation thereof | NICOX S.A. (FR) | 2010-05-25 | — | — | US | disclosed |
| CN-100496490-C | Nitrooxy derivatives of losartan, valsartan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin II receptor blockers for the treatment of cardiovascular diseases | NICOX SA (FR) | 2009-06-10 | — | — | CN | disclosed |
| EP-1653950-B1 | NITROOXY DERIVATIVES OF LOSARTAN, VALSATAN, CANDESARTAN, TELMISARTAN, EPROSARTAN AND OLMESARTAN AS ANGIOTENSIN-II RECEPTOR BLOCKERS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | NICOX SA (FR) | 2008-01-09 | — | — | EP | disclosed |
| US-20070238882-A1 | Process for Preparing Nitrooxy Esters, Nitrooxy Thioesters Nitrooxy Carbonates and Nitrooxy Thiocarbinates, Intermediates Useful in Said Process and Preparation Thereof | NICOX S.A. (FR) | 2007-10-11 | — | — | US | disclosed |
| CN-1984871-A | Process for preparing nitrooxy esters, nitrooxy thioesters, nitrooxy carbonates and nitrooxy thiocarbonates, intermediates useful in said process and preparation thereof | NICOX SA (FR) | 2007-06-20 | — | — | CN | disclosed |
| EP-1778617-A1 | PROCESS FOR PREPARING NITROOXY ESTERS, NITROOXY THIOESTERS, NITROOXY CARBONATES AND NITROOXY THIOCARBONATES, INTERMEDIATES USEFUL IN SAID PROCESS AND PREPARATION THEREOF | NicOx S.A. (FR) | 2007-05-02 | — | — | EP | disclosed |
| US-20060276523-A1 | Nitoroxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-II receptor blockers for the treatment of cardiovascular diseases | NICOX S.A. (FR) | 2006-12-07 | — | — | US | disclosed |
| CN-1832742-A | Nitrooxy derivatives of losartan, valsartan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin II receptor blockers for the treatment of cardiovascular diseases | NICOX SA (FR) | 2006-09-13 | — | — | CN | disclosed |
| WO-2006079610-A1 | NITROOXY SARTAN DERIVATIVES AS ANGIOTENSIN II RECEPTOR BLOCKERS FOR THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES | NICOX S.A. (FR) | 2006-08-03 | — | — | WO | disclosed |
| EP-1653950-A2 | NITROOXY DERIVATIVES OF LOSARTAN, VALSATAN, CANDESARTAN, TELMISARTAN, EPROSARTAN AND OLMESARTAN AS ANGIOTENSIN-II RECEPTOR BLOCKERS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Nicox S.A. (FR) | 2006-05-10 | — | — | EP | disclosed |
| WO-2006008196-A1 | PROCESS FOR PREPARING NITROOXY ESTERS, NITROOXY THIOESTERS, NITROOXY CARBONATES AND NITROOXY THIOCARBONATES, INTERMEDIATES USEFUL IN SAID PROCESS AND PREPARATION THEREOF | NICOX S.A. (FR) | 2006-01-26 | — | — | WO | disclosed |
| WO-2005011646-A2 | NITROOXY DERIVATIVES OF LOSARTAN, VALSATAN, CANDESARTAN, TELMISARTAN, EPROSARTAN AND OLMESARTAN AS ANGIOTENSIN-II RECEPTOR BLOCKERS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | NICOX S.A. (FR) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238882-A1 | Process for Preparing Nitrooxy Esters, Nitrooxy Thioesters Nitrooxy Carbonates and Nitrooxy Thiocarbinates, Intermediates Useful in Said Process and Preparation Thereof | OTUB1, TET1, TET3 | KMT2A 2729/4885MEN1 3860/4885TSHR 2795/4885 |
| US-20060276523-A1 | Nitoroxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-II receptor blockers for the treatment of cardiovascular diseases | AGTR2, AGTR1, REN | KMT2A 3358/4885MEN1 4208/4885TSHR 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.